CytoSorbents Corporation · NASDAQ:CTSO
CytoSorbents — Q4 2017 Earnings Presentation
13 slides from CytoSorbents's earnings presentation, Mar 8, 2018
Slide 1: CytoSorbents Corporation Q4 and Full Year 2017 Earnings Conference Call
CytoSorbents Corporation (NASDAQ: CTSO) A Leader in Critical Care Immunotherapy Q4 2017 and Full Year 2017 Earnings Conference Call March 8, 2018
Slide 2: Conference Call Participants
Conference Call Participants Dr. Phillip Chan, MD, PhD Chief Executive Officer and President Vincent Capponi, MS Chief Operating Officer Kathleen Bloch, MBA, CPA Chief Financial Officer Dr. Eric Mortensen, MD, PhD Chief Medical Officer Dr. Christian Steiner, MD Vice President of Sales and Marketing
Slide 3: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 4: Operational Highlights
Operational Highlights • Record 2017 total revenue of $15.1M with $13.4M in CytoSorb sales, due to strong re-order rates • 2017 blended product gross margins expanded to 71% from 67% • 35,000+ CytoSorb treatments delivered, from 20,000 a year ago • Healthy cash balance of $17.3M (12/31/17) • Expecti
Slide 5: Cardiac Surgery Trials Update
Cardiac Surgery Trials Update • U.S. REFRESH 2 Update: • Pivotal, 400 patient, randomized, controlled PMA multi-center trial targeting reduction of post-op AKI using CytoSorb during complex cardiac surgery including valve replacement and aortic reconstruction with hypothermic cardiac arrest • Obtain
Slide 6: HemoDefend Nearing U.S. Pivotal Trial
HemoDefend Nearing U.S. Pivotal Trial • 100M pRBC units transfused each year worldwide • Many companies targeting decreased infectious blood risk – NAT testing, pathogen reduction • HemoDefend pRBC is a point-of-transfusion in-line filter focused on reduction of non-infectious contaminants that can
Slide 7: Financial Highlights
Financial Highlights med CVtOSorbents forking to Save Lives Through Blood Purification
Slide 8: Comparative Annual Revenue Results
Comparative Annual Revenue Results Year Ended Year Ended Dec 31, 2017 Dec 31, 2016 % Incr. Product revenue $13,381,853 $ 8,206,036 63% Grant and other income 1,768,901 1,321,807 34% Total revenue $ 15,150,754 $ 9,527,843 59% • CytoSorb® product sales for the year 2017 increased by $5.2M, or 63% to $
Slide 9: Annual Product Sales
Annual Product Sales Over the past three years, the compound growth rate of return (“CAGR”) on product sales was 62% $16,000,000 CytoSorb® Product Sales $14,000,000 $13,381,853 $12,000,000 $10,000,000 $8,206,036 $8,000,000 $6,000,000 $4,043,819 $4,000,000 $3,135,387 $2,000,000 $821,787 $- 2013 2014
Slide 10: Quarterly Product Sales
Quarterly Product Sales In Q4 2017, We Achieved Record Product Sales With Solid Quarter over Quarter Growth $4,500,000 $4,296,047 CytoSorb® Product Sales $4,000,000 $3,448,661 $3,500,000 $3,041,012 $3,000,000 $2,596,133 $2,612,801 $2,500,000 $2,143,116 $1,852,670 $2,000,000 $1,597,449 $1,495,590 $1,
Slide 11: Working Capital and Cap Table
Working Capital and Cap Table Working Capital as of 12/31/17 12/31/16 12/31/15 12/31/14 Current Assets: Cash and short-term investments $ 17,322 $ 5,245 $ 7,509 $ 5,550 Grants and accounts receivable, net 2,206 1,433 649 819 Inventories 796 834 1,191 538 Prepaid expenses and other current assets 415
Slide 12: Guidance
Guidance • We have not historically provided guidance on quarterly results until the quarter has been completed • We continue to expect that Q1 2018 CytoSorb sales will exceed product sales in the Q1 2017 • Remain very optimistic about our growth opportunities and reiterate guidance on continued gro
Slide 13: Q&A Session
Q&A Session CytoSorbents Corporation NASDAQ: CTSO Investor Relations: Jeremy Feffer (212) 915-3820 jeremy@lifesciadvisors.com A Leader in Critical Care Immunotherapy 13